Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Nov 12;3(21):3333-3336.
doi: 10.1182/bloodadvances.2019000289.

Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia

Fares Alsawah  1 , Lydia Benitez  2 , Sarah Choi  3 , Bernard Marini  2 , Anthony Perissinotti  2 , Amy Skyles  2 , Patrick Burke  4 , Kristen Pettit  4 , Ashley Crouch  4 , Heather Fox  4 , Dale Bixby  4
Affiliations
Case Reports

Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia

Fares Alsawah et al. Blood Adv. .

Abstract

  1. This is the first report of successful treatment of therapy-resistant leptomeningeal T-PLL with intrathecal alemtuzumab.

  2. Intrathecal alemtuzumab is a potentially safe and efficacious therapeutic alternative for treatment of leptomeningeal T-PLL.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Timeline of disease management. AlloHCT, allogeneic hematopoietic stem cell transplant; WBRT, whole-brain radiation therapy.
Figure 2.
Figure 2.
CSF morphologic and flow cytometry findings during the treatment course. Pretreatment CSF showed definitive morphologic evidence of abnormal lymphocytes, with flow cytometry showing a prominent CD4 and CD8 double-positive population (green), consistent with involvement by T-PLL. Following triple therapy, the burden of disease was reduced but with persistent morphologic and flow cytometric evidence of disease. Following alemtuzumab therapy, the CSF was entirely cleared, with no morphologic or flow cytometric evidence of T-PLL (Wright Giemsa stain; original magnification ×1000).
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:.
    1. Khot A, Dearden C. T-cell prolymphocytic leukemia. Expert Rev Anticancer Ther. 2009;9(3):365-371. - PubMed
    1. Dearden C. Management of prolymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2015;2015:361-367. - PubMed
    1. Malkan UY, Gunes G, Yayar O, Demiroglu H, Yesilirmak A, Uner A. A T-cell prolymphocytic leukemia case with central nervous system involvement. Int J Clin Exp Med. 2015;8(8):14207-14209. - PMC - PubMed
    1. Göçmen S, Kutlay M, Erikçi A, Atabey C, Sayan O, Haholu A. Central nervous system involvement of T-cell prolymphocytic leukemia diagnosed with stereotactic brain biopsy: case report. Turk J Haematol. 2014;31(1):75-78. - PMC - PubMed

Publication types

MeSH terms

Substances